Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M. Di Leo A, et al. Among authors: smirnova i. J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7. J Natl Cancer Inst. 2014. PMID: 24317176 Free PMC article. Clinical Trial.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: smirnova i. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
Gordeev A, Vaal A, Puchkova M, Smirnova I, Doronin A, Znobishcheva A, Zhmudanova D, Aleksandrov A, Sukchev M, Imyanitov E, Solovyev V, Iakovlev P. Gordeev A, et al. Among authors: smirnova i. Sci Rep. 2024 Nov 6;14(1):26915. doi: 10.1038/s41598-024-77480-w. Sci Rep. 2024. PMID: 39505987 Free PMC article. No abstract available.
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
Gordeev A, Vaal A, Puchkova M, Smirnova I, Doronin A, Znobishcheva A, Zhmudanova D, Aleksandrov A, Sukchev M, Imyanitov E, Solovyev V, Iakovlev P. Gordeev A, et al. Among authors: smirnova i. Sci Rep. 2024 Oct 4;14(1):23136. doi: 10.1038/s41598-024-72118-3. Sci Rep. 2024. PMID: 39367001 Free PMC article.
624 results